F-18 FES PET shows efficacy in early-stage breast cancer detection

09/4/2013 | MolecularImaging.net

A study in the Journal of Nuclear Medicine suggests that using F-18 FES PET to assess estrogen receptor expression could aid in the detection of early-stage breast cancer, but disease severity and tumor size may pose limitations. In the 48-patient perioperative study, F-18 FES PET showed 85% overall sensitivity in spotting early-stage breast cancer, but it did not identify small volume tumors, researchers said. Researchers also found that F-18 FES PET uptake correlated with immunohistochemistry ER expression and the main tumor's size.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC